January 4, 2017 / 1:56 PM / 7 months ago

BRIEF-Evoke Phase 3 diabetic gastroparesis trial did not meet primary endpoint

1 Min Read

Jan 4 (Reuters) - Evoke Pharma Inc :

* Evoke provides additional data demonstrating statistically significant benefit for Gimoti in moderate to severe patients in phase 3 diabetic gastroparesis trial

* Evoke Pharma Inc- phase 3 trial failed to reach its primary endpoint

* Evoke Pharma Inc- phase 3 safety data revealed no significant adverse effects and were consistent with favorable results from previous Gimoti studies

* Evoke Pharma Inc - patients with moderate to severe symptoms, responded statistically significantly better when treated with Gimoti Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below